Kailera Therapeutics, Inc. (KLRA)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS4829311020
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Kailera Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:32. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 10 Feb 2027 16:00 | -0.82 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -1.01 | -0.74 | +26.7% | Beat |
| 12 Aug 2026 16:00 | -0.73 | -1.09 | -49.4% | Miss |
| 26 May 2026 16:00 | -0.55 | -3.65 | -565.1% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -149M | — | -1.26 | — | -122.3M |
| 2024 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 12.94 | 14.89 | 11.88 | 12.88 | +0.16% | 7,660,817 | |
| Oct 2026 | 11.39 | 13.83 | 9.76 | 12.86 | +12.61% | 28,031,700 | |
| Sep 2026 | 15.21 | 17.06 | 10.83 | 11.42 | -25.84% | 25,151,000 | |
| Aug 2026 | 17.06 | 19.51 | 15.15 | 15.40 | -9.09% | 12,829,300 | |
| Jul 2026 | 22.00 | 23.82 | 16.39 | 16.94 | -23.10% | 13,151,900 | |
| Jun 2026 | 22.89 | 23.98 | 18.50 | 22.03 | -3.97% | 21,828,300 | |
| May 2026 | 25.02 | 25.70 | 19.01 | 22.94 | -8.24% | 8,782,700 | |
| Apr 2026 | 26.00 | 28.23 | 20.87 | 25.00 | — | 19,071,400 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Kailera Therapeutics to Present at ObesityWeek 2026 (opens in a new tab) 10 Nov 2026 12:00
- Canaccord Genuity Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $44 (opens in a new tab) Benzinga · 09 Nov 2026 14:02
- Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity (opens in a new tab) MT Newswires · 30 Sep 2026 12:44
- Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth” (opens in a new tab) Insider Monkey · 15 Sep 2026 05:16
- Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore (opens in a new tab) 24/7 Wall St. · 18 Aug 2026 15:10
- Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? (opens in a new tab) Simply Wall St. · 17 Aug 2026 14:10
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 13.21 USD
- Market cap
- 1.7B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -3.3× | Weak | 14.16× |
| Price / book | 1.66× | Fair | 3.5× |
| EV / EBITDA | -2.57× | Weak | 11.19× |
| Free cash flow yield | -7.1% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 54.9% |
| Operating margin | 0% | Weak | 5.8% |
| Net margin | 0% | Weak | 1.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.01× | Good | 0.4× |
| Current ratio | 21.84× | Good | 2.64× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow KLRA and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.